5-hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotheraphy

Journal of Oncology Pharmacy Practice

Volumn 12, Issue 4, 2006, Pages 201-209

  Higa, Gerald M ^a,b   Auber, Miklos L ^a,b   Altaha, Ramin ^a,b   Piktel, Debbie ^a   Kurian, Sohba ^a,b   Hobbs, Gerry ^a   Landreth, Kenneth ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HIAA; 5 HT3 receptor; NK1 receptor; P; Substance

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; APREPITANT; CISPLATIN; CREATININE; DEXAMETHASONE; DOLASETRON MESILATE; FLUOROURACIL; FOLINIC ACID; NEUROTRANSMITTER; OXALIPLATIN; PALONOSETRON; SEROTONIN; SUBSTANCE P;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY FLUID; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHESIS; IMMUNOASSAY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; IMMUNOASSAY; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; SUBSTANCE P; TIME FACTORS; VOMITING;

EID: 33846243803     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206072080     Document Type: Article

References (36)

1. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193-230.
2. Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Huntingt) 2004; 18: 9-14.
3. Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs 1997; 53: 206-34.
4. Cubeddu LX. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 1996; 53: 18-25.
5. de Boer-Dennert M, de Wit R, Schmitz PI et al. (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76: 1055-61.
6. du Bois A, Vach W, Siebert C et al. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens. Support Care Cancer 1997; 5: 212-18.
7. Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993; 72: 2239-41.
8. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691-97.
9. Latreille J, PaterJ, Johnston D et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998; 16: 1174-78.
10. Olver I, Paska W, Depierre A et al. A multicentre, doubleblind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996; 9: 945-52.
11. Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: A double-blind randomized comparative trial of ondansetron (GR38032F) versus placebo. Eur J Cancer 1993; 29A: 35-38.
12. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996; 53: 26-31.
13. Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835-42.
14. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60: 535-46.
15. Heitz P, Polak JM, Timson DM, Pearse AG. Enterochromaffin cells as the endocrine source of gastrointestinal substance P. Histochemistry 1976; 49: 343-47.
16. Andrews PLR, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993; 32: 799-806.
17. Sasek CA, Wessendorf MW, Helke CJ. Evidence for coexistence of thyrotropin-releasing hormone, substance P and serotonin in ventral medullary neurons that project to the intermediolateral cell column of the rate. Neuroscience 1990; 35: 105-19.
18. Sanger GJ. The involvement of 5-HT3 receptors in visceral function. In Hamon M ed. Central and peripheral 5-HT3 receptors. Academic Press, 1992: 207-55.
19. Tattersall FD, Rycroft W, Francis B et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35: 1121-29.
20. Uemura M, Tsujii T, Kikuchi E et al. Increased plasma levels of substance P and disturbed water excretion in patients with liver cirrhosis. Scand J Gastroenterol 1998; 33: 860-66.
21. Kris MG, Hesketh PJ, Herrstedt J et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13: 85-96.
22. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17: 2971-94.
23. Hesketh PJ, Van Belle S, Aapro M et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-80.
24. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-19.
25. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-300.
26. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758298 and MK-0869. Cancer 2002; 94: 3032-41.
27. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759-67.
28. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999; 340: 190-95.
29. Alfieri AB, Cubeddu LX. Treatment with para-chlorophenylalanine antagonizes the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629-32.
30. Aapro M. Methodological issues in antiemetic studies. Invest New Drugs 1993; 11: 243-53.
31. Janes RJ, Muhonen T, Karjalainen UP, Wiklund T. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple day high-dose chemotherapy. Eur J Cancer 1998; 34: 196-98.
32. Navari RM, Madajewicz S, Anderson N et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13: 2408-16.
33. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
34. Yanaihara C, Sato H, Hirohashi M, Sakagami M, Yamamoto K. Substance P radioimmunoassay using N-a-tyrosyl-substance P and demonstration of the presence of substance P-like immunoreactivity in human blood and porcine tissue extracts. Endocrinol Jpn 1976; 23: 457-63.
35. Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncol 1995; 13: 681-87.
36. Schroder CP, van der Graaf WT, Kema IP, Groenewegen A, Sleijfer DT, de Vries EG. Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron. Cancer Chemother Pharmacol 1995; 36: 477-82.